"目录号: HY-13685
Miltefosine 是一种PI3K/Akt抑制剂，大大减少HIV-1从病毒感染的巨噬细胞产生。
相关产品
SB 203580-MK 2206 dihydrochloride-Dolutegravir-SC79-Maraviroc-AZD5363-Afuresertib-GSK-690693-Elvitegravir-A-443654-AKT inhibitor VIII-Atazanavir sulfate-GDC-0068-Honokiol-Tenofovir Disoproxil Fumarate-
生物活性
Description
Miltefosine is aPI3K/Aktinhibitor, dramatically reducesHIV-1production from long-living virus-infected macrophages.
IC50& Target
PI3K/Akt[1]
In Vitro
Treatment of HIV-1 infected macrophages with Miltefosine inhibits the recruitment of PH-AktGFP to the plasma membrane. Since Miltefosine inhibits Akt through mimicry of the PH domain, it is likely that Miltefosine binds to PIP3, blocking the recruitment of PH-Akt to the membrane[1]. Miltefosine (HePC) inhibits protein kinase C (PKC) from NIH3T3 cells in cell-free extracts with a IC50of about 7 μM. Inhibition is competitive with regard to phosphatidylserine with a Kiof 0.59 μM[2]. Miltefosine is an alkylphospholipid that inhibit activation of Akt. Miltefosine is a direct inhibitor of Akt, and induces dose-dependent inhibition of primary effusion lymphoma (PEL) in culture and also inhibits the downstream targets of Akt, such as mTOR, leading to reduced phosphorylation and activation of S6K and S6. Importantly, Miltefosine also inhibits Akt targets that are not part of the mTOR pathway, eg, FOXO1, and are therefore expected to have a greater therapeutic impact than mTORC1 inhibitors alone[3].
In Vivo
Mice are randomized into groups of 5 and injected intraperitoneally 5 days a week with 50 mg/kg of either Miltefosine or Perifosine dissolved in PBS, or equivalent volume of vehicle (PBS). Both Miltefosine and Perifosine inhibit the growth rate of tumors compared with vehicle-treated mice. By day 14 after treatment, there is an approximately 50% decrease in average tumor volume in Perifosine- and Miltefosine-treated mice, compared with vehicle-treated mice (P<0.04). Tumor growth is also significantly retarded (P<0.04 for Perifosine and P≤0.055 for Miltefosine by linear mixed-effects model analysis). Immunohistochemical analyses display an overall reduction in staining for phosphorylated ribosomal S6 protein in tumor sections from Miltefosine- and Perifosine-treated mice compared with the PBS-treated mice. This reduced phosphorylation correlated with the delay in tumor progression in drug-treated animals[3].
Clinical Trial
Centro Internacional de Entrenamiento e Investigaciones Médicas-Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cutaneous Leishmaniasis
October 2011
Phase 4
Drugs for Neglected Diseases
Cutaneous Leishmaniasis
December 2016
Phase 2
Knight Therapeutics (USA) Inc
Leishmaniasis or Other Uses of Miltefosine
July 2015
International Centre for Diarrhoeal Disease Research, Bangladesh-Thrasher Research Fund
Post Kala Azar Dermal Leishmaniasis
July 2014
Phase 3
Knight Therapeutics (USA) Inc
Mucocutaneous Leishmaniasis
December 2015
Knight Therapeutics (USA) Inc
Mucocutaneous Leishmaniasis
July 2015
Banaras Hindu University-Rajendra Memorial Research Institute of Medical Sciences
Visceral Leishmaniasis
October 2007
Phase 2
Centro Internacional de Entrenamiento e Investigaciones Médicas-Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)-INS-Instituto Nacional de Dermatología Centro dermatológico Federico Lleras Acosta
Cutaneous Leishmaniasis
July 2007
Phase 3
Foundation Fader-AB Foundation
Cutaneous Leishmaniasis
March 2007
Phase 2
Hospital Universitário Professor Edgard Santos-Oswaldo Cruz Foundation
Cutaneous Leishmaniasis
March 2017
Phase 3
Knight Therapeutics (USA) Inc
Leishmaniasis
July 2015
Knight Therapeutics (USA) Inc
Mucosal Leishmaniasis-Cutaneous Leishmaniasis
May 2010
Phase 2
Drugs for Neglected Diseases-Medecins Sans Frontieres, Netherlands-London School of Hygiene and Tropical Medicine-Addis Ababa University-Institute of Tropical Medicine, Belgium-Slotervaart Hospital-University of Gondar
Visceral Leishmaniasis
July 2014
Phase 3
Universidad de Antioquia
Cutaneous Leishmaniasis
June 2006
Phase 3
Brasilia University Hospital
Leishmaniasis-Leishmaniasis, Mucocutaneous
July 2009
Phase 2
Hospital Universitário Professor Edgard Santos-Conselho Nacional de Desenvolvimento Científico e Tecnológico-Ministerio de Ciencia e Innovación, Spain-Ministério da Saúde-AEterna Zentaris
Treatment of Cutaneous Leishmaniasis in Brazil.
July 2007
Phase 2
AB Foundation
Leishmaniasis
April 2005
Phase 1-Phase 2
Drugs for Neglected Diseases
Visceral Leishmaniasis
May 2015
Phase 2
University of Brasilia
Leishmaniasis
August 2015
Phase 2
Foundation Fader
Cutaneous Leishmaniasis
March 2008
Phase 2
Drugs for Neglected Diseases-The Netherlands Cancer Institute-The Institute of Endemic Diseases (IEND), University of Khartoum-Kenya Medical Research Institute-Makerere University-University of Gondar
Visceral Leishmaniasis
August 1, 2017
Phase 3
Drugs for Neglected Diseases-Shaheed Surhawardy Medical College and Hospital-International Centre for Diarrhoeal Disease Research, Bangladesh
Visceral Leishmaniasis
May 2010
Phase 3
AB Foundation
Cutaneous Leishmaniasis
September 2005
Phase 2
AB Foundation-World Health Organization
PKDL
July 2007
Phase 2
Centro de Investigaciones Bioclínicas de la Fundación Fader
Cutaneous Leihmaniasis
Phase 2
Drugs for Neglected Diseases-Gilead Sciences-Paladin Laboratories Inc
Primary Visceral Leishmaniasis
March 2010
Phase 2
AB Foundation-AEterna Zentaris
Kala Azar
April 2005
Phase 1-Phase 2
AB Foundation
Leishmaniasis
April 2004
Phase 1-Phase 2
Marcus Maurer-Charite University, Berlin, Germany
Chronic Urticaria
September 2008
Phase 2
Banaras Hindu University
Visceral Leishmaniasis
September 2006
Phase 2
Banaras Hindu University-Drugs for Neglected Diseases-Rajendra Memorial Research Institute of Medical Sciences
Leishmaniasis, Visceral
September 2007
Phase 3
Drugs for Neglected Diseases
Visceral Leishmaniasis
June 2008
Phase 3
View MoreCollapse
References
